A detailed history of Morgan Stanley transactions in Immuneering Corp stock. As of the latest transaction made, Morgan Stanley holds 46,052 shares of IMRX stock, worth $122,498. This represents 0.0% of its overall portfolio holdings.

Number of Shares
46,052
Previous 45,619 0.95%
Holding current value
$122,498
Previous $131,000 55.73%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.28 - $2.75 $554 - $1,190
433 Added 0.95%
46,052 $58,000
Q1 2024

Aug 16, 2024

SELL
$1.91 - $7.32 $20,110 - $77,072
-10,529 Reduced 18.75%
45,619 $131,000
Q1 2024

May 15, 2024

SELL
$1.91 - $7.32 $20,110 - $77,072
-10,529 Reduced 18.75%
45,619 $131,000
Q4 2023

Aug 16, 2024

BUY
$4.84 - $8.44 $48,864 - $85,210
10,096 Added 21.92%
56,148 $412,000
Q4 2023

Feb 13, 2024

BUY
$4.84 - $8.44 $168,746 - $294,260
34,865 Added 163.82%
56,148 $412,000
Q3 2023

Nov 15, 2023

SELL
$7.21 - $10.68 $31,666 - $46,906
-4,392 Reduced 17.11%
21,283 $163,000
Q2 2023

Aug 14, 2023

SELL
$6.49 - $13.36 $12,824 - $26,399
-1,976 Reduced 7.15%
25,675 $260,000
Q1 2023

May 15, 2023

SELL
$3.78 - $10.38 $67,151 - $184,400
-17,765 Reduced 39.12%
27,651 $268,000
Q4 2022

Feb 14, 2023

BUY
$4.09 - $15.0 $137,698 - $505,005
33,667 Added 286.55%
45,416 $220,000
Q3 2022

Nov 14, 2022

SELL
$5.0 - $14.32 $32,690 - $93,624
-6,538 Reduced 35.75%
11,749 $168,000
Q2 2022

Oct 27, 2022

SELL
$3.89 - $7.81 $532 - $1,069
-137 Reduced 0.74%
18,287 $98,000
Q2 2022

Aug 15, 2022

SELL
$3.89 - $7.81 $532 - $1,069
-137 Reduced 0.74%
18,287 $98,000
Q1 2022

Oct 27, 2022

BUY
$6.47 - $16.99 $886 - $2,327
137 Added 0.75%
18,424 $119,000
Q1 2022

May 13, 2022

BUY
$6.47 - $16.99 $50,381 - $132,301
7,787 Added 73.21%
18,424 $119,000
Q4 2021

Feb 14, 2022

BUY
$16.12 - $31.02 $63,335 - $121,877
3,929 Added 58.57%
10,637 $172,000
Q3 2021

Nov 15, 2021

BUY
$17.0 - $32.84 $114,036 - $220,290
6,708 New
6,708 $178,000

Others Institutions Holding IMRX

About Immuneering Corp


  • Ticker IMRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,392,300
  • Market Cap $70.2M
  • Description
  • Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...
More about IMRX
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.